<DOC>
	<DOCNO>NCT00832819</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) , safety tolerability , pharmacokinetics , pharmacodynamics , anti-tumor effect E7080 administer continually twice daily combination carboplatin paclitaxel patient advance metastatic non-small cell lung cancer .</brief_summary>
	<brief_title>E7080 Combination With Carboplatin Paclitaxel Patients With Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion criterion : 1 . Subjects histologically cytologically confirm diagnosis nonsmall cell lung cancer ( NSCLC ) . 2 . Locally advanced and/or metastatic nonsmall cell lung cancer ( NSCLC ) ( Stage IIIB/IV ) . 3 . Subjects least one measurable tumor lesion Response Evaluation Criteria In Solid Tumors ( RECIST ) . 4 . Subjects Performance Status ( PS ) 01 . 5 . Subjects adequate organ function . Exclusion criterion : 1 . Subjects ever receive follow therapy nonsmall cell lung cancer ( NSCLC ) : 1 . Chemotherapy 2 . Biological immunotherapy 3 . Surgery primary focus 4 . The radiation therapy primary focus 2 . Subjects severe complication disease history . 3 . Subjects brain metastasis accompany clinical symptom require treatment . 4 . Subjects simultaneous metachronous cancer . 5 . Subjects take oral medication . 6 . Subjects use drug strongly inhibit induce cytochrome P450 ( CYP ) 3A4 .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Lung Cancer</keyword>
</DOC>